• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过无针注射递送的汉坦病毒和普马拉病毒DNA疫苗的1期临床试验。

Phase 1 clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injection.

作者信息

Hooper Jay W, Kwilas Steven A, Josleyn Matthew, Norris Sarah, Hutter Jack N, Hamer Melinda, Livezey Jeffrey, Paolino Kristopher, Twomey Patrick, Koren Michael, Keiser Paul, Moon James E, Nwaeze Ugo, Koontz Jason, Ledesma-Feliciano Carmen, Landry Nathalie, Wellington Trevor

机构信息

Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, 21702, USA.

Clinical Trials Center, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.

出版信息

NPJ Vaccines. 2024 Nov 17;9(1):221. doi: 10.1038/s41541-024-00998-7.

DOI:10.1038/s41541-024-00998-7
PMID:39551791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11570633/
Abstract

Hantaan virus (HTNV) and Puumala virus (PUUV) are pathogenic zoonoses found in Asia and Europe, respectively. We conducted a randomized Phase 1 clinical trial of individual HTNV and PUUV DNA vaccines targeting the envelope glycoproteins (GnGc), as well as a combined HTNV/PUUV DNA vaccine delivered at varying doses using the PharmaJet Stratis® needle-free injection system (NCT02776761). Cohort 1 and 2 vaccines consisted of 2 mg/vaccination of HTNV or PUUV plasmid, respectively. Cohort 3 vaccine consisted of 2 mg/vaccination of 1:1 mixture of HTNV and PUUV vaccines. Vaccinations were administered on Days 0, 28, 56, and 168. The vaccines were safe and well tolerated. Neutralizing antibody responses were elicited in 7/7 (100%) subjects who received the HTNV DNA (Cohort 1) and 6/6 (100%) subjects who received the PUUV DNA (Cohort 2) vaccines alone. The combination vaccine resulted in 4/9 (44%) seroconversion against both viruses. After the first two vaccinations, the seroconversion rates for the HTNV and PUUV vaccines were >80%.

摘要

汉坦病毒（HTNV）和普马拉病毒（PUUV）分别是在亚洲和欧洲发现的致病性人畜共患病原体。我们针对包膜糖蛋白（GnGc）开展了一项关于单个HTNV和PUUV DNA疫苗以及使用PharmaJet Stratis®无针注射系统以不同剂量递送的联合HTNV/PUUV DNA疫苗的1期随机临床试验（NCT02776761）。第1组和第2组疫苗分别由每次接种2mg的HTNV或PUUV质粒组成。第3组疫苗由每次接种2mg的HTNV和PUUV疫苗1:1混合物组成。在第0、28、56和168天进行接种。这些疫苗安全且耐受性良好。单独接受HTNV DNA疫苗（第1组）的7/7（100%）受试者和接受PUUV DNA疫苗（第2组）的6/6（100%）受试者产生了中和抗体反应。联合疫苗导致4/9（44%）的受试者对两种病毒均发生血清转化。在前两次接种后，HTNV和PUUV疫苗的血清转化率均>80%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/39685c0f51a9/41541_2024_998_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/04611269af11/41541_2024_998_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/764a4291a9ac/41541_2024_998_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/8fc29404abe6/41541_2024_998_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/77177cd88421/41541_2024_998_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/54a1f5ef7903/41541_2024_998_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/39685c0f51a9/41541_2024_998_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/04611269af11/41541_2024_998_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/764a4291a9ac/41541_2024_998_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/8fc29404abe6/41541_2024_998_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/77177cd88421/41541_2024_998_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/54a1f5ef7903/41541_2024_998_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33c/11570633/39685c0f51a9/41541_2024_998_Fig6_HTML.jpg

相似文献

1
Phase 1 clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injection.通过无针注射递送的汉坦病毒和普马拉病毒DNA疫苗的1期临床试验。
NPJ Vaccines. 2024 Nov 17;9(1):221. doi: 10.1038/s41541-024-00998-7.
2
A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation.汉滩病毒和普马拉病毒 M 片段 DNA 疫苗经肌肉电穿孔免疫用于肾综合征出血热的 1 期临床试验。
Clin Microbiol Infect. 2014 May;20 Suppl 5:110-7. doi: 10.1111/1469-0691.12553. Epub 2014 Mar 7.
3
A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation.一项2a期随机、双盲、剂量优化研究，以评估通过肌肉电穿孔递送的肾综合征出血热二价DNA疫苗的免疫原性和安全性。
Vaccines (Basel). 2020 Jul 11;8(3):377. doi: 10.3390/vaccines8030377.
4
A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome.汉坦病毒和普马拉病毒 M 片段 DNA 疫苗治疗肾综合征出血热的 1 期临床试验。
Vaccine. 2012 Mar 2;30(11):1951-8. doi: 10.1016/j.vaccine.2012.01.024. Epub 2012 Jan 14.
5
Anti-HFRS Human IgG Produced in Transchromosomic Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models.转染色体牛产生的抗汉坦病毒出血热综合征人IgG具有强大的汉坦病毒中和活性且在动物模型中具有保护作用。
Front Microbiol. 2020 May 7;11:832. doi: 10.3389/fmicb.2020.00832. eCollection 2020.
6
A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).一种新型的辛诺柏病毒 DNA 疫苗及其作为抗汉坦病毒肺综合征（HPS）和肾综合征出血热（HFRS）的候选泛汉坦病毒疫苗的应用。
Vaccine. 2013 Sep 13;31(40):4314-21. doi: 10.1016/j.vaccine.2013.07.025. Epub 2013 Jul 24.
7
DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys.用汉坦病毒M基因进行DNA疫苗接种可保护仓鼠抵御四种肾综合征出血热汉坦病毒中的三种，并在恒河猴中引发高滴度的中和抗体反应。
J Virol. 2001 Sep;75(18):8469-77. doi: 10.1128/jvi.75.18.8469-8477.2001.
8
Three asymptomatic animal infection models of hemorrhagic fever with renal syndrome caused by hantaviruses.三种汉坦病毒引起的肾综合征出血热的无症状动物感染模型。
PLoS One. 2019 May 10;14(5):e0216700. doi: 10.1371/journal.pone.0216700. eCollection 2019.
9
Immunogenicity of a multi-epitope DNA vaccine against hantavirus.汉坦病毒多表位 DNA 疫苗的免疫原性。
Hum Vaccin Immunother. 2012 Feb;8(2):208-15. doi: 10.4161/hv.18389. Epub 2012 Feb 1.
10
A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates.使用弹簧动力喷射注射器递送的汉坦病毒肺综合征（HPS）DNA疫苗在兔和非人灵长类动物中引发了强烈的中和抗体反应。
Curr Gene Ther. 2014;14(3):200-10. doi: 10.2174/1566523214666140522122633.

引用本文的文献

1
Pathogenicity and virulence of Rodent-Borne Orthohantaviruses.啮齿动物传播的正汉坦病毒的致病性和毒力
Virulence. 2025 Dec;16(1):2553784. doi: 10.1080/21505594.2025.2553784. Epub 2025 Sep 4.
2
Immune responses following DNA vaccination by needle-free injection against hemolysin co-regulated protein 1.通过无针注射针对溶血素共同调节蛋白1进行DNA疫苗接种后的免疫反应。
Front Immunol. 2025 Jun 25;16:1612540. doi: 10.3389/fimmu.2025.1612540. eCollection 2025.
3
Promising Vaccine Formulations for Emerging Infectious Diseases.针对新发传染病的有前景的疫苗制剂。

本文引用的文献

1
Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus.单剂量基于重组水疱性口炎病毒的疫苗可引发针对汉坦病毒的强大且持久的中和抗体。
NPJ Vaccines. 2024 Feb 10;9(1):28. doi: 10.1038/s41541-024-00814-2.
2
Safety and Immunogenicity of an Andes Virus DNA Vaccine by Needle-Free Injection: A Randomized, Controlled Phase 1 Study.经皮无针注射安第斯病毒 DNA 疫苗的安全性和免疫原性：一项随机、对照的 1 期研究。
J Infect Dis. 2024 Jan 12;229(1):30-38. doi: 10.1093/infdis/jiad235.
3
Investigation of a subunit protein vaccine for HFRS based on a consensus sequence between envelope glycoproteins of HTNV and SEOV.
Int J Mol Sci. 2025 May 20;26(10):4893. doi: 10.3390/ijms26104893.
4
Puumala orthohantavirus: prevalence, biology, disease, animal models and recent advances in therapeutics development and structural biology.普马拉正汉坦病毒：流行情况、生物学特性、疾病、动物模型以及治疗学开发与结构生物学的最新进展
Front Immunol. 2025 May 8;16:1575112. doi: 10.3389/fimmu.2025.1575112. eCollection 2025.
5
Insect-specific virus platforms for arbovirus vaccine development.用于虫媒病毒疫苗开发的昆虫特异性病毒平台。
Front Immunol. 2025 Mar 14;16:1521104. doi: 10.3389/fimmu.2025.1521104. eCollection 2025.
基于汉滩病毒和汉城病毒包膜糖蛋白共有序列的肾综合征出血热亚单位疫苗的研究。
Virus Res. 2023 Sep;334:199149. doi: 10.1016/j.virusres.2023.199149. Epub 2023 Jun 20.
4
Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies.抗原作图和人类新型布尼亚病毒中和抗体的功能特性鉴定。
Elife. 2023 Mar 27;12:e81743. doi: 10.7554/eLife.81743.
5
Improved DNA Vaccine Delivery with Needle-Free Injection Systems.使用无针注射系统改进DNA疫苗递送
Vaccines (Basel). 2023 Jan 28;11(2):280. doi: 10.3390/vaccines11020280.
6
Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses.人源抗体识别普马拉病毒糖蛋白上的四元表位，为抗正布尼亚病毒提供广泛保护。
Sci Transl Med. 2022 Mar 16;14(636):eabl5399. doi: 10.1126/scitranslmed.abl5399.
7
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.一种铁蛋白纳米颗粒 H2 流感疫苗在健康成年人中的安全性和免疫原性：一项 1 期临床试验。
Nat Med. 2022 Feb;28(2):383-391. doi: 10.1038/s41591-021-01660-8. Epub 2022 Feb 3.
8
Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines.小动物喷射注射技术可提高汉坦病毒 DNA 疫苗的免疫原性。
Vaccine. 2021 Feb 12;39(7):1101-1110. doi: 10.1016/j.vaccine.2021.01.002. Epub 2021 Jan 19.
9
A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation.一项2a期随机、双盲、剂量优化研究，以评估通过肌肉电穿孔递送的肾综合征出血热二价DNA疫苗的免疫原性和安全性。
Vaccines (Basel). 2020 Jul 11;8(3):377. doi: 10.3390/vaccines8030377.
10
Anti-HFRS Human IgG Produced in Transchromosomic Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models.转染色体牛产生的抗汉坦病毒出血热综合征人IgG具有强大的汉坦病毒中和活性且在动物模型中具有保护作用。
Front Microbiol. 2020 May 7;11:832. doi: 10.3389/fmicb.2020.00832. eCollection 2020.